Bank of Japan Holds Steady on Rates
The Bank of Japan kept its policy rate unchanged at 0.75% due to uncertainty surrounding the Middle East conflict. Bloomberg's Shery Ahn has more.
Todas as matérias desta categoria, das mais recentes às mais antigas.
The Bank of Japan kept its policy rate unchanged at 0.75% due to uncertainty surrounding the Middle East conflict. Bloomberg's Shery Ahn has more.
Energy prices have surged following an Iranian missile attack on Qatar's Ras Laffan Industrial City. Energy Vista Founder Leslie Palti-Guzman joins Bloomberg TV to discuss the impact on global supply chains and how long the disruption could persist.
HSBC is said to be considering a wave of deep job cuts over the coming years as CEO Georges Elhedery bets on AI to shrink its middle and back office footprint. Bloomberg's Adam Haigh reports.
Benchmark oil prices are surging past $100 as the Middle East conflict disrupts global trade flows and widens crude spreads. Nomura International Wealth Management North Asia CIO Julia Wang discusses the specific risks facing Asian economies.
Iran and Israel have traded strikes on energy infrastructure in the Middle East, with little sign of the conflict abating. Bloomberg's Laura Davison reports on the latest developments.
Planet Labs (NYSE:PL), a pioneer in daily Earth data and insights, announced record financial results for its fourth quarter and full fiscal year ended January 31, 2026.
AECOM (NYSE:ACM), a global leader in infrastructure consulting, announced today its selection for a pivotal role in the U.S. Missile Defense Agency’s (MDA) Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program.
Pelthos Therapeutics (NYSE:PTHS) reported its fourth-quarter and full-year 2025 financial results, highlighting a period of rapid commercial acceleration for its flagship product, ZELSUVMI™ (berdazimer gel, 10.3%).
Pfizer (NYSE:PFE) today announced positive topline results from its Phase 3 TALAPRO-3 study, evaluating the combination of TALZENNA® (talazoparib) and XTANDI® (enzalutamide).
Tejon Ranch (NYSE:TRC), a diversified real estate development and agribusiness company, reported financial results for the fourth quarter and full year ended December 31, 2025.
Theravance Biopharma (NASDAQ:TBPH) on Thursday reported financial results for the fourth quarter and full year ended December 31, 2025, revealing a year of significant financial recovery tempered by a major strategic pivot.
NeurAxis (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for children and adults, announced its financial and operational results for the fourth quarter and full fiscal year ended December 31, 2025.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade